Crystal form of kubutan saponin A compound, its pharmaceutical composition and use
By screening various crystallization methods of saponin A in various solvent systems, especially crystal forms A, C and J and its mixtures, the problems of crystal form stability and drug efficacy consistency of saponin A are solved, and the problem of saponin A is achieved. Its stable existence and clinical application at room temperature.
Patent Information
- Application Number
- CN202110891737.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-08-04
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2041-08-04
AI Technical Summary
The degradation and absorption differences of different crystal forms of saponin A in vivo lead to inconsistent clinical efficacy, and it is difficult for the prior art to effectively screen and stabilize its crystal forms.
11 crystal forms of saponin A were obtained by screening the various crystallization methods in various solvent systems, especially crystal forms A, C and J and their mixtures, using X-ray powder diffraction, differential scanning calorimetry, Thermogravimetric analysis and dynamic moisture adsorption methods identify its characteristics to ensure that it exists stably under normal temperature conditions.
The identification and preparation of various stable crystal forms of saponin A has been achieved to ensure its stability in the body and consistency of drug efficacy. In particular, the dry powder form of crystal forms A, C and J is stable at room temperature. Suitable for treating lung diseases such as COPD and asthma.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The present invention relates to the field of chemical medicine and crystal preparation technology, and in particular to a crystal form of a kubutan saponin A compound, a pharmaceutical composition thereof and uses thereof. Background Art
[0002] Ilex kudingcha is the young leaves or leaves of Ilex kudingcha, a plant of the genus Ilex in the Aquifoliaceae family. It is a traditional folk medicinal plant in southern and southwestern my country. It is widely used and has a long history. It has the effects of clearing away heat and detoxifying, killing bacteria and anti-inflammatory, invigorating the stomach and eliminating accumulation, relieving cough and reducing phlegm, promoting fluid and quenching thirst, refreshing the mind and improving eyesight and intelligence. It can be used to treat headaches, toothaches, red eyes, fever, thirst, and dysentery; it also has the effects of activating blood circulation and regulating blood lipids, and can be used to treat diseases such as hypertension and hyperlipidemia; it also has the effect of dilating bronchial smooth muscles, and is suitable for the treatment of various respiratory and lung diseases (such as COPD and asthma).
[0003] A variety of kudingsaponin compounds (such as kudingsaponin A) with the above-mentioned effects can be extracted and separated from Ilex kudingchaenensis, and a large number of literatures have reported on them. For example, please refer to Tu Pengfei et al. (“Study on the Chemical Composition and Its Effect on Hypolipidemic Effect of Ilex kudingchaenensis”, the 25th Annual Academic Conference of the Chinese Chemical Society, 2006). The structure of kudingsaponin A, i.e., 3β-12α-19α-trihydroxy-ursane-13(18)-ene-28,20β-lactone-3-O-[β-D-glucosyl-(1→3)-[α-L-rhamnosyl-(1→2)]-α-L-arabinoside, is shown in formula (I):
[0004]
[0005] Different crystal forms of a pharmaceutical compound will result in different physical and chemical properties, and different solubility and stability, which will affect its degradation and absorption in the body and lead to differences in its clinical efficacy. Therefore, when developing pharmaceutical compounds, it is necessary to comprehensively and systematically screen different crystal forms and explore their effects in the body in order to select the most suitable crystal form for development. Summary of the invention
[0006] The present invention screens 11 crystal forms of kubutan saponin A by using various crystallization methods in various solvent systems, which are respectively recorded as crystal forms A, B, C, D, E, G, I1, I2, J, K and L. Among them, crystal forms I1 and I2 are weakly crystalline (or low crystalline) and cannot exist stably.
[0007] Therefore, the present invention provides crystalline forms A, B, C, D, E, G, J, K and L of kubutan saponin A. The present invention also includes a mixture of any proportion of any two or more of the crystalline forms. The crystalline forms of the present invention can stably exist under suitable conditions, especially crystalline forms A, C and J, which can stably exist in the form of dry powder under normal temperature conditions. Therefore, in a preferred embodiment, the present invention provides crystalline forms A, C and J of kubutan saponin A and any mixture thereof.
[0008] Specifically, the present invention provides a crystalline form A of a kuding saponin A compound, wherein the crystalline form A has characteristic peaks at the following 2θ angles on an X-ray powder diffraction (XRPD) pattern: 6.7°±0.2°, 7.3°±0.2°, 7.9°±0.2°, 10.5°±0.2°, 10.9°±0.2°, and 14.1°±0.2°.
[0009] In a preferred embodiment, the X-ray powder diffraction (XRPD) pattern of the crystalline form A also has characteristic peaks at the following 2θ angles: 3.6°±0.2°, 12.8°±0.2°, 13.2°±0.2°, 13.6°±0.2°, 15.2°±0.2°, 16.1°±0.2°, 18.3°±0.2°, 24.1°±0.2°.
[0010] In a preferred embodiment, the crystalline form A has substantially Figure 1a X-ray powder diffraction (XRPD) pattern shown.
[0011] In a preferred embodiment, the X-ray powder diffraction (XRPD) pattern of the crystalline form A has characteristic peaks at the 2θ angle shown in Table 1:
[0012] Table 1: X-ray powder diffraction (XRPD) peak list of Form A
[0013]
[0014]
[0015]
[0016] In a preferred embodiment, the crystalline form A has substantially Figure 1b The differential scanning calorimetry (DSC) analysis diagram is shown.
[0017] In a preferred embodiment, the crystalline form A has substantially Figure 1c Thermogravimetric analysis (TGA) graph shown.
[0018] In a preferred embodiment, the crystalline form A has substantially Figure 1d Dynamic moisture sorption (DVS) diagram shown.
[0019] The crystal form C of the kuding saponin A compound provided by the present invention has characteristic peaks at the following 2θ angles on the X-ray powder diffraction (XRPD) pattern: 7.8°±0.2°, 12.7°±0.2°, 14.4°±0.2°, 14.9°±0.2°, 16.3°±0.2°, 18.6°±0.2°, and 25.1°±0.2°.
[0020] In a preferred embodiment, the X-ray powder diffraction (XRPD) pattern of the Form C also has characteristic peaks at the following 2θ angles: 3.9°±0.2°, 8.3°±0.2°, 13.2°±0.2°, 19.5°±0.2°, 20.3°±0.2°.
[0021] In a preferred embodiment, the crystalline form C has substantially Figure 2a X-ray powder diffraction (XRPD) pattern shown.
[0022] In a preferred embodiment, the X-ray powder diffraction (XRPD) pattern of Form C has characteristic peaks at the 2θ angle shown in Table 2:
[0023] Table 2: X-ray powder diffraction (XRPD) peak list of Form C
[0024]
[0025]
[0026] In a preferred embodiment, the crystalline form C has substantially Figure 2b The differential scanning calorimetry (DSC) analysis diagram is shown.
[0027] In a preferred embodiment, the crystalline form C has substantially Figure 2c Thermogravimetric analysis (TGA) graph shown.
[0028] In a preferred embodiment, the crystalline form C has substantially Figure 2d Dynamic moisture sorption (DVS) diagram shown.
[0029] The crystal form J of the kubutan saponin A compound provided by the present invention has characteristic peaks at the following 2θ angles on the X-ray powder diffraction (XRPD) pattern: 7.7°±0.2°, 9.3°±0.2°, 12.1°±0.2°, 14.1°±0.2°, 15.1°±0.2°, and 16.6°±0.2°.
[0030] In a preferred embodiment, the X-ray powder diffraction (XRPD) pattern of the crystalline form J also has characteristic peaks at the following 2θ angles: 3.5°±0.2°, 4.7°±0.2°, 12.7°±0.2°, 13.7°±0.2°, 15.5°±0.2°, 16.2°±0.2°, and 18.1°±0.2°.
[0031] In a preferred embodiment, the crystalline form J has substantially Figure 3a X-ray powder diffraction (XRPD) pattern shown.
[0032] In a preferred embodiment, the X-ray powder diffraction (XRPD) pattern of Form J has characteristic peaks at the 2θ angle shown in Table 3:
[0033] Table 3: X-ray powder diffraction (XRPD) peak list of Form J
[0034]
[0035]
[0036] In a preferred embodiment, the crystalline form J has substantially Figure 3b The differential scanning calorimetry (DSC) analysis diagram is shown.
[0037] In a preferred embodiment, the crystalline form J has substantially Figure 3c Thermogravimetric analysis (TGA) graph shown.
[0038] In a preferred embodiment, the crystalline form J has substantially Figure 3d Dynamic moisture sorption (DVS) diagram shown.
[0039] The X-ray powder diffraction (XRPD) diagram of the crystal form B of kudingsaponin A provided by the present invention has characteristic peaks at the following 2θ angles: 7.4°±0.2°, 7.9°±0.2°, 11.8°±0.2°, 12.5°±0.2°, 14.3°±0.2°, and 15.4°±0.2°.
[0040] In a preferred embodiment, the X-ray powder diffraction (XRPD) pattern of Form B also has characteristic peaks at the following 2θ angles: 4.8°±0.2°, 8.1°±0.2°, 14.6°±0.2°.
[0041] In a preferred embodiment, the crystalline form B has characteristic peaks at the 2θ angle shown in Table 14 on the X-ray powder diffraction (XRPD) pattern.
[0042] The X-ray powder diffraction (XRPD) diagram of the crystal form D of kudingsaponin A provided by the present invention has characteristic peaks at the following 2θ angles: 6.2°±0.2°, 9.9°±0.2°, and 12.4°±0.2°.
[0043] In a preferred embodiment, the X-ray powder diffraction (XRPD) pattern of Form D also has characteristic peaks at the following 2θ angles: 4.5°±0.2°, 7.2°±0.2°, 12.9°±0.2°, 19.0°±0.2°.
[0044] In a preferred embodiment, the crystalline form D has characteristic peaks at the 2θ angle shown in Table 15 on the X-ray powder diffraction (XRPD) pattern.
[0045] The X-ray powder diffraction (XRPD) diagram of the crystal form E of kuding saponin A provided by the present invention has characteristic peaks at the following 2θ angles: 5.6°±0.2°, 11.1°±0.2°, and 14.4°±0.2°.
[0046] In a preferred embodiment, the X-ray powder diffraction (XRPD) pattern of the crystalline form E also has characteristic peaks at the following 2θ angles: 4.5°±0.2°, 7.7°±0.2°, 13.6°±0.2°, 18.1°±0.2°, 19.8°±0.2°, 20.8°±0.2°, 28.0°±0.2°.
[0047] In a preferred embodiment, the crystalline form E has characteristic peaks at the 2θ angle shown in Table 16 on the X-ray powder diffraction (XRPD) pattern.
[0048] The X-ray powder diffraction (XRPD) pattern of the crystalline form G of kudingsaponin A provided by the present invention has characteristic peaks at the following 2θ angles: 5.7°±0.2°, 7.8°±0.2°, 9.2°±0.2°, 9.9°±0.2°, 17.5°±0.2°, 19.8°±0.2°, 20.0°±0.2°, 28.5°±0.2°, and 37.8°±0.2°.
[0049] In a preferred embodiment, the X-ray powder diffraction (XRPD) pattern of the crystalline form G also has characteristic peaks at the following 2θ angles: 3.4°±0.2°, 7.3°±0.2°, 12.0°±0.2°, 14.4°±0.2°, 17.0°±0.2°, 18.8°±0.2°, 22.5°±0.2°, 25.5°±0.2°, 25.7°±0.2°, 26.1°±0.2°.
[0050] In a preferred embodiment, the X-ray powder diffraction (XRPD) pattern of the crystalline form G has characteristic peaks at the 2θ angle shown in Table 17.
[0051] The X-ray powder diffraction (XRPD) diagram of the crystal form K of kudingsaponin A provided by the present invention has characteristic peaks at the following 2θ angles: 7.6°±0.2°, 11.1°±0.2°, 12.1°±0.2°, and 14.3°±0.2°.
[0052] In a preferred embodiment, the X-ray powder diffraction (XRPD) pattern of the crystalline form K also has characteristic peaks at the following 2θ angles: 4.5°±0.2°, 4.9°±0.2°, 5.5°±0.2°, 8.2°±0.2°, 13.5°±0.2°, and 18.7°±0.2°.
[0053] In a preferred embodiment, the X-ray powder diffraction (XRPD) pattern of the crystalline form K has characteristic peaks at the 2θ angle shown in Table 20.
[0054] The X-ray powder diffraction (XRPD) pattern of the crystalline form L of kudingsaponin A provided by the present invention has characteristic peaks at the following 2θ angles: 9.5°±0.2°, 12.3°±0.2°, 13.6°±0.2°, 14.5°±0.2°, 15.4°±0.2°, and 16.2°±0.2°.
[0055] In a preferred embodiment, the X-ray powder diffraction (XRPD) pattern of the crystalline form L also has characteristic peaks at the following 2θ angles: 3.7°±0.2°, 7.9°±0.2°, 16.9°±0.2°, 17.3°±0.2°, 18.8°±0.2°, 20.4°±0.2°.
[0056] In a preferred embodiment, the X-ray powder diffraction (XRPD) pattern of the crystalline form L has characteristic peaks at the 2θ angle shown in Table 21.
[0057] The present invention also provides a method for preparing the crystal forms A, C and J of the kubutan saponin A compound.
[0058] In a preferred embodiment, the crystalline form A of Kudingsaponin A can be obtained by extracting and purifying Kudingcha powder and then crystallizing it in a specific solvent.
[0059] Preferably, the preparation method of the crystal form A is: take Kudingcha powder, extract it by percolation, and concentrate it to obtain an extract; dilute the extract and centrifuge it to obtain a crude sample; purify the crude sample by high pressure chromatography twice, and then decolorize it with activated carbon, recrystallize it, and freeze-dry it; finally, crush it to obtain the Kudingsaponin A crystal form (i.e., crystal form A).
[0060] In a preferred embodiment, the percolation extraction is performed with an alcohol solvent (such as ethanol). For example, pure ethanol or a 50-90% (v / v) ethanol-water solution is used for percolation extraction. Usually, the mass ratio of Kudingcha powder to alcohol is 1:2.5-1:1.5. The extract can be diluted with water and anhydrous ethanol and centrifuged to obtain a crude sample. The amount of water can be 0.5-1 times the mass of Kudingcha powder, and the amount of anhydrous ethanol can be 0.3-0.8 times the mass of Kudingcha powder.
[0061] Preferably, the crude sample is dissolved with alcohol and then placed under conditions below 10°C for recrystallization. The alcohol can be ethanol or an aqueous solution thereof, such as a 20-50% (v / v) ethanol solution. The dissolution is carried out at a higher temperature, such as 60-90°C. The crystals obtained can be freeze-dried (such as freeze-dried at about 0°C), then dried at room temperature (such as about 20-28°C), and finally dried at a temperature above 32°C to obtain Form A. Typically, the freeze-drying time can be 1-3 hours, the room temperature drying time can be about 3-5 hours, and the drying time above 32°C can be 5-8 hours.
[0062] In another preferred embodiment, the crystalline form A of kubutan saponin A can be obtained by crystallizing amorphous kubutan saponin A in a specific solvent.
[0063] Preferably, the preparation method of the crystalline form A can be any one of the following three methods:
[0064] Method 1: dissolving amorphous kubutan saponin A in an alcohol solvent to obtain a solution of kubutan saponin A, concentrating the solution until a white precipitate is precipitated and substantially no droplets are generated at the inlet of the evaporation liquid collection container, which is the concentration end point, to obtain a concentrated solution; freeze-drying the concentrated solution to obtain crystalline form A;
[0065] Method 2: dissolving amorphous kubutan saponin A in an alcohol solvent to obtain a solution of kubutan saponin A, ultrasonically treating the solution, filtering it, and concentrating the filtrate under reduced pressure to obtain a dry solid, which is crystalline form A;
[0066] Method 3: dissolving amorphous kubutan saponin A in an alcohol solvent to obtain a solution of kubutan saponin A, and allowing the solution to evaporate naturally at room temperature to obtain a dry solid, namely, crystalline form A.
[0067] Preferably, the alcohol solvent is methanol or ethanol. Preferably, methods one and two use ethanol, such as an ethanol aqueous solution (such as a 70% ethanol solution) to dissolve amorphous kubutin saponin A. Preferably, in method three, methanol is used to dissolve amorphous kubutin saponin A. There is no particular restriction on the amount of the alcohol solvent, and the amount should be sufficient to fully dissolve the amorphous kubutin saponin A.
[0068] Preferably, in method 1, after obtaining the dissolved solution of kuding saponin A, first filter to obtain a clear solution, and then concentrate the clear solution. The filtration can be performed using a filter membrane with a pore size of <5 microns. The dissolved solution or its clear solution can be concentrated using a rotary evaporator. The concentration can be performed in a water bath at 50-60°C, the rotation speed can be controlled to 30-80rpm, and the vacuum degree can be controlled to be not less than 0.08MPa.
[0069] In a preferred embodiment, the crystalline form C of kubutan saponin A can be obtained by recrystallizing the crystalline form A in a specific solvent.
[0070] Preferably, the preparation method of the crystalline form C can be any one of the following three methods:
[0071] Method 4: dissolving Form A with a solvent (such as acetonitrile and isopropyl ether) to obtain a suspension; stirring at room temperature for 3-5 days, and centrifuging; taking the obtained solid and vacuum drying it at 25-30°C overnight to obtain Form C;
[0072] Method 5: dissolving Form A in ethyl acetate to obtain a suspension; stirring at room temperature for 2-4 days, and centrifuging; taking the obtained solid and vacuum drying it at 25-30°C overnight to obtain Form C;
[0073] Method 6: Heat Form A at 150-200°C for 3-10 minutes to obtain Form C.
[0074] Preferably, in the method 4, the volume ratio of acetonitrile to isopropyl ether is 1:1 to 1:5. Preferably, the mass volume ratio (g:ml) of Form A to the solvent is 1:20 to 1:50.
[0075] Preferably, in the method five, the mass volume ratio (g:ml) of Form A to ethyl acetate is 1:10 to 1:30.
[0076] Preferably, in the method six, the crystal form A is heated at a temperature of 170±5° C. and kept warm for 3-7 minutes.
[0077] In a preferred embodiment, the crystalline form J of kubutan saponin A can be obtained by recrystallizing the crystalline form A in a specific solvent.
[0078] Preferably, the preparation method of the crystal form J can be any one of the following two methods:
[0079] Method 7: dissolving Form A in a saturated aqueous solution of ethyl acetate to obtain a suspension; stirring at room temperature for 3-5 days, and centrifuging; taking the obtained solid and vacuum drying it at 25-30°C overnight to obtain Form J;
[0080] Method 8: Dissolve Form A in water to obtain a suspension; stir at room temperature for 2-4 days, and centrifuge; take the obtained solid and vacuum dry it overnight at 25-30°C to obtain Form J.
[0081] Preferably, in the method seven, the mass volume ratio (g:ml) of Form A to the saturated aqueous solution of ethyl acetate is 1:20 to 1:50.
[0082] Preferably, in the method eight, the mass volume ratio (g:ml) of Form A to water is 1:10 to 1:30.
[0083] In another preferred embodiment, the crystalline form J of kubutan saponin A can be obtained by crystallizing amorphous kubutan saponin A in a specific solvent.
[0084] Preferably, the preparation method of the crystal form J can be any one of the following two methods:
[0085] Method 9: dissolving amorphous kudingsaponin A in an alcohol solvent; adding water, stirring at room temperature overnight, centrifuging, and then vacuum drying the obtained solid at 25-30° C. overnight to obtain crystal form J;
[0086] Method 10: After dissolving amorphous kudingsaponin A with an alcohol solvent and water, stirring at 0-10°C overnight, centrifuging, and vacuum drying the obtained solid at 25-30°C overnight to obtain Form J.
[0087] Preferably, in the method nine, the alcohol solvent is an anhydrous alcohol solvent, such as anhydrous ethanol. The mass volume ratio (g: ml) of kudingsaponin A to the alcohol solvent is 1:30 to 1:100. The amount of water added can be 1-10 times the volume of the alcohol solvent. Usually, a white solid will precipitate after adding water, and then stir at room temperature overnight.
[0088] Preferably, in the method 10, the alcohol solvent is preferably an anhydrous alcohol solvent, such as anhydrous ethanol. The volume ratio of the alcohol solvent to water may be 1:1 to 1:5. The mass volume ratio (g:ml) of kudingsaponin A to the alcohol solvent is 1:10 to 1:50. After mixing the alcohol solvent, water and kudingsaponin A, they may be heated in a water bath at, for example, 60-80°C until kudingsaponin A is completely dissolved. Stirring is usually carried out overnight at about 4°C.
[0089] In some embodiments, Form B is prepared from Form A. Specifically, Form A can be heated to 110-130° C. and kept warm for 3-10 minutes, thereby obtaining Form B.
[0090] In some embodiments, an alcohol solvent (such as isopropanol) and kubutan saponin A are mixed, and after being completely dissolved in a water bath at, for example, 55° C. or above, a solid is slowly precipitated, and the mixture is slowly cooled to room temperature, stirred for 3-6 days, and centrifuged to obtain Form D. The mass volume ratio (mg:mL) of the alcohol solvent to kubutan saponin A can be in the range of 4-8:1.
[0091] In some embodiments, kubutan saponin A, an alcohol solvent and water are mixed, dissolved at a temperature above 60° C., slowly cooled to room temperature, and allowed to stand to precipitate a solid, thereby obtaining Form E. The alcohol solvent may be, for example, anhydrous ethanol. There is no particular limitation on the amount of the alcohol solvent and water, as long as it is sufficient to dissolve kubutan saponin A.
[0092] In some embodiments, kubutan saponin A is mixed with an organic solvent (such as tetrahydrofuran) and water, and the solvent is volatilized at room temperature after being completely dissolved, thereby obtaining Form G. There is no particular restriction on the amount of organic solvent and water, as long as it is sufficient to dissolve kubutan saponin A. Of course, if the amount of solvent is too much, it will affect the volatilization time, resulting in a long preparation time. The specific amount can be determined by those skilled in the art according to the actual production situation.
[0093] In some embodiments, after dissolving kubutan saponin A in anhydrous ethanol, the solution is concentrated and dried under reduced pressure at 25-30° C. to obtain Form K.
[0094] In some embodiments, the crystal form L can be obtained by heating the crystal form J to above 110° C. and keeping the temperature for 3-10 minutes.
[0095] The present invention provides the use of various crystal forms of kubutan saponin A compounds in the preparation of medicines for treating lung diseases.
[0096] In a preferred embodiment, the pulmonary disease is chronic obstructive pulmonary disease or asthma.
[0097] The present invention also provides a pharmaceutical composition for treating lung diseases, characterized in that the pharmaceutical composition comprises a mixture of one or more of the crystalline forms A, B, C, D, E, G, J, K and L of the kubutan saponin A compound, and a pharmaceutically acceptable carrier. Preferably, the pharmaceutical composition contains any one or more of the crystalline forms A, C and J of kubutan saponin A. Preferably, in the pharmaceutical composition, the kubutan saponin A compound can maintain a crystalline state.
[0098] In a preferred embodiment, the crystalline form of the kubutan saponin A compound is crystalline form A, crystalline form C or crystalline form J.
[0099] In a preferred embodiment, the pharmaceutical composition is in the form of an inhalation preparation.
[0100] In a preferred embodiment, the inhalation preparation is an inhalation powder, an inhalation aerosol, an inhalation spray, an inhalation suspension or an inhalation solution.
[0101] The term "pharmaceutically acceptable carrier" should be compatible with the kudingsaponin A compound (crystalline form) in the pharmaceutical composition of the present invention, that is, it can be mixed with it without significantly reducing the effect of the pharmaceutical composition in the treatment of lung diseases (such as asthma and chronic obstructive pulmonary disease) under normal circumstances.
[0102] In a preferred embodiment, the pharmaceutically acceptable carrier includes one or more of a lubricant, a glidant, a propellant, a solubilizer, a cosolvent, a diluent, a stabilizer and an antibacterial agent.
[0103] In a preferred embodiment, the pharmaceutical carrier is lactose.
[0104] In another preferred embodiment, the pharmaceutical carrier is polyethylene glycol 200, ethanol and 1,1,1,2-tetrafluoroethane (R134a). BRIEF DESCRIPTION OF THE DRAWINGS
[0105] Figure 1a : X-ray powder diffraction (XRPD) pattern of crystalline form A of kudingsaponin A, the abscissa is 2θ value (degrees), and the ordinate is intensity (counts).
[0106] Figure 1b : Differential scanning calorimetry (DSC) analysis diagram of crystal form A of kudingsaponin A, the abscissa is temperature (°C), and the ordinate is heat flow (W / g).
[0107] Figure 1c : Thermogravimetric analysis (TGA) diagram of crystal form A of kudingsaponin A, the abscissa is temperature (°C), and the ordinate is weight (%).
[0108] Figure 1d : Dynamic moisture adsorption (DVS) diagram of crystalline form A of kudingsaponin A, the abscissa is relative humidity (%) and the ordinate is weight (%).
[0109] Figure 2a : X-ray powder diffraction (XRPD) pattern of crystalline form C of kudingsaponin A, the abscissa is the 2θ value (degrees), and the ordinate is the intensity (counts).
[0110] Figure 2b : Differential scanning calorimetry (DSC) analysis diagram of crystalline form C of kudingsaponin A, the abscissa is temperature (°C), and the ordinate is heat flow (W / g).
[0111] Figure 2c : Thermogravimetric analysis (TGA) diagram of the crystal form C of kudingsaponin A, the abscissa is temperature (°C), and the ordinate is weight (%).
[0112] Figure 2d : Dynamic moisture adsorption (DVS) diagram of crystalline form C of kudingsaponin A, the abscissa is relative humidity (%) and the ordinate is weight (%).
[0113] Figure 3a : X-ray powder diffraction (XRPD) pattern of crystalline form J of kudingsaponin A, the abscissa is 2θ value (degrees), and the ordinate is intensity (counts).
[0114] Figure 3b : Differential scanning calorimetry (DSC) analysis diagram of crystal form J of kudingsaponin A, the abscissa is temperature (°C), and the ordinate is heat flow (W / g).
[0115] Figure 3c : Thermogravimetric analysis (TGA) diagram of crystal form J of kudingsaponin A, the abscissa is temperature (°C), and the ordinate is weight (%).
[0116] Figure 3d : Dynamic moisture adsorption (DVS) diagram of crystalline form J of kudingsaponin A, the abscissa is relative humidity (%) and the ordinate is weight (%).
[0117] Figure 4a : X-ray powder diffraction (XRPD) diagram of crystalline form J of kudingsaponin A under long-term test and accelerated test conditions, the abscissa is the 2θ value (degrees), and the ordinate is the intensity (counts).
[0118] Figure 4b : Thermogravimetric analysis (TGA) diagram of the crystal form J of kudingsaponin A under long-term test and accelerated test conditions, the abscissa is temperature (°C), and the ordinate is weight (%).
[0119] Figure 5a : X-ray powder diffraction (XRPD) diagram of the competitive starting mixed sample of Form A and Form J and a single crystal form. The abscissa is the 2θ value (degrees), and the ordinate is the intensity (counts).
[0120] Figure 5b : X-ray powder diffraction (XRPD) pattern of Form A and Form J after 3 days of competition. The abscissa is the 2θ value (degrees), and the ordinate is the intensity (counts). Specific implementation plan
[0121] In the following description, certain specific details are set forth in order to provide a thorough understanding of various embodiments of the present invention. However, it will be appreciated by those skilled in the art that the present invention can be practiced without these details. The following description of several embodiments is carried out with the understanding that the present disclosure is considered as an example of the claimed subject matter, and is not intended to limit the appended claims to the specific embodiments shown. The titles used throughout the present disclosure are provided only for convenience and should not be interpreted as limiting the claims in any way. The embodiments shown under any title may be combined with the embodiments shown under any other title.
[0122] Unless the context requires otherwise, throughout the specification and claims, the word "comprise" and its variations are to be interpreted in an open, inclusive sense, i.e., "including but not limited to"; at the same time, "comprise" and its variations such as "comprising" also include "mainly composed of..." and "consisting of..."
[0123] References throughout this specification to "one embodiment" or "an embodiment" mean that a particular feature, structure, or characteristic described in conjunction with that embodiment is included in at least one embodiment of the present invention. Thus, the phrases "in one embodiment" or "in an embodiment" appearing in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.
[0124] As used herein, "pharmaceutically acceptable carrier" includes, but is not limited to, any adjuvant, carrier, excipient, glidant, sweetener, diluent, preservative, dye / colorant, flavor enhancer, surfactant, wetting agent, dispersant, suspending agent, stabilizer, isotonic agent, solvent or emulsifier that has been approved by the FDA or NMPA or other relevant agencies as acceptable for use in humans or livestock.
[0125] Herein, "pharmaceutical composition" refers to a preparation of the compound of the present invention and a vehicle generally accepted in the art for delivering the biologically active compound to mammals (eg, humans). Such a vehicle includes all pharmaceutically acceptable excipients therefor.
[0126] Herein, "effective amount" or "therapeutically effective amount" refers to the amount of the compound according to the present invention, which, when applied to a patient in need thereof, is sufficient to achieve the treatment of the disease state, disease or disorder that is useful for the compound. Such an amount will be sufficient to cause the biological or medical response of the tissue system or patient sought by researchers or clinicians. The amount of the compound according to the present invention constituting a therapeutically effective amount will vary according to factors such as the following: the compound and its biological activity, the composition for administration, the time of administration, the route of administration, the compound excretion rate, the duration of treatment, the type of the disease state or disease treated and its severity, the medicine used in combination or in unison with the compounds of the present invention, and the age, weight, general health, sex and diet of the patient. Those of ordinary skill in the art can routinely determine this therapeutically effective amount based on their own knowledge, prior art and the disclosure.
[0127] Unless otherwise indicated, the term "treating" as used herein means reversing, alleviating, inhibiting the progression of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition. "Prevention" refers to any treatment of a disease or condition that results in the clinical symptoms of the disease or condition not developing.
[0128] As used herein, "subject" or "patient" refers to an animal, such as a mammal (including a human), that has been or is to be the subject of treatment, observation, or experiment. The methods described herein can be used for human treatment and / or veterinary applications. In some embodiments, the subject is a mammal (or patient). In some embodiments, the subject (or patient) is a human, livestock (e.g., dogs and cats), farm animals (e.g., cattle, horses, sheep, goats, and pigs), and / or laboratory animals (e.g., mice, rats, hamsters, guinea pigs, pigs, rabbits, dogs, and monkeys). In some embodiments, the subject (or patient) is a human. "A person (or patient) in need thereof" refers to a person who may suffer from or is suspected of suffering from a disease or condition that would benefit from certain treatments; for example, treatment with a compound disclosed herein according to the present application.
[0129] References herein to "about" a value or parameter include (and describe) embodiments for that value or parameter itself. For example, reference to a description of "about X" includes a description of "X". In addition, the singular forms "a", "an", and "the" include plural references unless the context clearly dictates otherwise. Thus, for example, reference to "the compound" includes a plurality of such compounds, and reference to "the assay" includes reference to one or more assays and equivalents thereof known to those skilled in the art.
[0130] As used herein, "pharmaceutically acceptable" or "physiologically acceptable" refers to compounds, salts, compositions, dosage forms and other materials that can be used to prepare pharmaceutical compositions suitable for veterinary or human pharmaceutical use.
[0131] As used herein, "unit dosage forms" are physically discrete units suitable as unitary dosages for subjects (e.g., human subjects and other mammals), each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.
[0132] As used herein, the term "substantially as shown in" when referring to, for example, an XRPD pattern, a DSC thermogram, a DVS graph, or a TGA graph, includes patterns, thermograms, or graphs that are not necessarily identical to those described herein, but that fall within the limits of experimental error or deviation when considered by one of ordinary skill in the art.
[0133] In some embodiments, with respect to a particular crystalline form of a compound, the term "substantially pure" or "substantially free" means that the composition comprising the crystalline form contains less than less than 20%, less than 15%, less than 10%, less than 5%, or less than 1% by weight of other substances, including other crystalline forms and / or impurities. In some embodiments, "substantially pure" or "substantially free" refers to a substance that is free of other substances (including other crystalline forms and / or impurities). For example, impurities may include byproducts or remaining reagents from chemical reactions, contaminants, degradation products, other crystalline forms, water, and solvents.
[0134] Herein, for the characteristic powder X-ray diffraction peak positions of a crystalline form, the tolerance for the angular position (2θ) is ±0.2°. This tolerance is used when comparing two powder X-ray diffraction patterns. If a diffraction peak of one pattern is assigned to a certain angular position range (2θ) of ±0.2° of the measured peak position, and a diffraction peak of another pattern is assigned to another angular position range (2θ) of ±0.2° of the measured peak position, and if these peak ranges overlap, then the two peaks are considered to have the same angular position (2θ). For example, if the diffraction peak of one pattern is measured at 5.20°, for comparison, the tolerance allows the peak to be assigned to the range of 5.00°-5.40°. If the reference peak of the other diffraction pattern is measured at 5.35°, for comparison, the tolerance allows the peak to be assigned to the range of 5.15°-5.55°. Because there is an overlap between the two peak position ranges, the two peaks being compared are considered to have the same angular position (2θ). In some embodiments, the tolerance for angular position (2θ) is ±0.1°.
[0135] As used herein, "ultrasound" or "ultrasonic treatment" is used to fully mix or completely dissolve the substance in the solution. The process parameters of the ultrasonic treatment vary according to different treatment objects and can be set by a person skilled in the art according to actual use. For example, the power of the ultrasonic treatment can be set to 60 watts to 2000 watts, the frequency to 20 kHz to 80 kHz, and the time to 5 minutes to 150 minutes.
[0136] The present invention adopts a variety of instrumental analysis methods to identify the crystal forms A, C, and J of the prepared kudingsaponin A (for example, X-ray powder diffraction analysis) on the one hand; and to explore their properties (such as differential scanning calorimetry analysis, thermogravimetric analysis, and dynamic moisture adsorption analysis) on the other hand.
[0137] X-ray powder diffraction (XRPD) is commonly used for crystal structure analysis, and its diffraction intensity is determined by the element type, number and arrangement of atoms in the crystal unit cell. The X-ray powder diffraction method for measuring crystals is well known to those skilled in the art. The present invention uses an X-ray powder diffractometer to measure the crystal forms A, C and J of kubutan saponin A. The specific measurement conditions are shown in Table 4 (unless otherwise specified, the sample was not ground before testing):
[0138] Table 4: X-ray powder diffractometer and its measurement parameters
[0139]
[0140] It has been determined that the crystal forms A, C and J have specific characteristic peaks in the X-ray powder diffraction pattern; specifically, the crystal forms A, C and J have characteristic peaks at the 2θ angle as shown in Tables 1, 2 and 3, respectively.
[0141] Differential scanning calorimetry (DSC) is an important thermal analysis method, which uses the rate of heat absorption or heat release of the sample (unit: mJ / s) as the ordinate and temperature or time as the abscissa to measure a variety of thermodynamic and kinetic parameters, such as crystallization rate, melting temperature, phase transition temperature of the material, etc. The method of differential scanning calorimetry analysis of crystals is well known to those skilled in the art. In the present invention, a differential scanning calorimeter is used to measure the crystal forms A, C, and J of kubutan saponin A, and the specific measurement conditions are shown in Table 5.
[0142] Table 5: Differential scanning calorimetry scanner and its measurement parameters
[0143]
[0144] The inventors used the above method to mainly determine the desolvation peak and melting point parameters of the crystalline forms A, C, and J of kudingsaponin A.
[0145] The differential scanning calorimetry analysis results of Form A are as follows: Figure 1b As shown: the temperature range of its desolvation peak is about 30℃~120℃; its melting point is about 205℃.
[0146] The differential scanning calorimetry analysis results of Form C are as follows: Figure 2b As shown: the temperature range of its desolvation peak is about 20℃~60℃; its melting point is about 310℃.
[0147] The differential scanning calorimetry analysis results of Form J are as follows: Figure 3b As shown: the temperature range of its desolvation peak is about 20℃~120℃; its melting point is about 309℃.
[0148] Thermogravimetric analysis (TGA) is referred to as thermogravimetric analysis, which refers to a thermal analysis method that measures the relationship between the mass of a sample to be tested and the temperature or time change under a program-controlled temperature, and is used to study the thermal stability of the sample and the information related to the mass such as the intermediate product components that may be produced. It is often shared with other thermal analysis methods to perform comprehensive thermal analysis. The method of performing thermogravimetric analysis on crystals is well known to those skilled in the art. The present invention uses a thermogravimetric analyzer to measure the crystal forms A, C, and J of kubutan saponin A, and the specific measurement conditions are shown in Table 6.
[0149] Table 6: Thermogravimetric analyzer and its measurement parameters
[0150]
[0151]
[0152] The thermogravimetric analysis results of Form A are as follows Figure 1c As shown: it loses about 6.8% of its weight before 80°C, and its decomposition temperature is about 318°C.
[0153] The thermogravimetric analysis results of Form C are as follows Figure 2c As shown: it loses about 1.2% of its weight before 70°C, and its decomposition temperature is about 315°C.
[0154] The thermogravimetric analysis results of Form J are as follows Figure 3c As shown: it loses about 5.8% of its weight before 120°C, and its decomposition temperature is about 324°C.
[0155] The dynamic water adsorption (DVS) method is a detection method for analyzing the water adsorption performance of a sample and recording the water adsorption isotherm. The stability of a compound is determined by identifying its ability to adsorb water. The method of dynamic water adsorption analysis of crystals is well known to those skilled in the art. The present invention uses a dynamic water adsorption instrument to perform hygroscopic analysis on the crystal forms A, C, and J of kubutan saponin A. The specific measurement conditions are shown in Table 7.
[0156] Table 7: Dynamic moisture adsorption instrument and its measurement parameters
[0157]
[0158]
[0159] The thermogravimetric analysis results of Form A are as follows Figure 1dAs shown: in the relative humidity range of 0% to 80%, its weight changes by about 12%, so Form A is hygroscopic.
[0160] The thermogravimetric analysis results of Form C are as follows Figure 2d As shown: in the relative humidity range of 0% to 80%, its weight change is about 1.8%, so Form C is slightly hygroscopic.
[0161] The thermogravimetric analysis results of Form J are as follows Figure 3d As shown: when the relative humidity is in the range of 0% to 80%, its weight changes by about 4.7%, so the crystal form J is hygroscopic.
[0162] The above features mentioned in the present invention or the features mentioned in the embodiments can be combined in any way. All the features disclosed in the specification of this case can be used in any combination form, and each feature disclosed in the specification can be replaced by any alternative feature that can provide the same, equal or similar purpose. Therefore, unless otherwise specified, the disclosed features are only general examples of equal or similar features.
[0163] Unless otherwise defined, all professional and scientific terms used herein have the same meanings as those familiar to those skilled in the art. In addition, any methods and materials similar or equivalent to those described herein may be applied to the methods of the present invention. The preferred and preferred embodiments and materials described herein are for demonstration purposes only.
[0164] In this specification, unless otherwise specified, the numerical value or numerical range, whether or not preceded by the word "about", covers an approximate range equivalent to the numerical value or numerical range that can be understood by technicians in the relevant field, such as a range of ±10% of the numerical value or end value, or a range of ±5%, ±3%, ±2%, ±1% or ±0.5%.
[0165] The present invention will be further described in detail below in conjunction with embodiments. However, it should be understood that these embodiments are only for illustrative purposes and are not intended to limit the scope of the present invention.
[0166] Example 1: Preparation of Ilexanoside A Crystalline Form A and Its X-ray Powder Diffraction Determination
[0167] The specific steps for preparing kudingsaponin A crystal form A are as follows:
[0168] Take 20 kg of Kudingcha powder, extract it with 34.4 kg of 80% ethanol solution by percolation, concentrate it to obtain an extract, add water to obtain 17 kg of the final extract; dilute it with 10.2 kg of anhydrous ethanol and centrifuge it to obtain a crude sample.
[0169] The crude sample was purified by high pressure chromatography twice, successively through a 30 μm packed column and a 10 μm packed column, and then decolorized with activated carbon to obtain a crude powder of kubutan saponin A; the crude powder of kubutan saponin A was dissolved in 35% ethanol in an 80°C water bath, and placed in a 6°C water bath to precipitate crystals; the crystals were freeze-dried at 0°C for two hours, then dried at 25°C for 4 hours, and finally dried at 35°C for 6 hours; and finally crushed to obtain about 170 g of kubutan saponin A crystal form (i.e., crystal form A).
[0170] The crystal form A prepared above was subjected to X-ray diffraction measurement, and the instruments used and their parameters are shown in Table 4. The obtained data are shown in Table 1, that is, there are characteristic peaks at the 2θ angle shown in Table 1.
[0171] Example 2: Preparation of Ilexanoside A Crystalline Form C and Its X-ray Powder Diffraction Determination
[0172] The specific steps for preparing kudingsaponin A crystal form C are as follows:
[0173] a. The preparation method as shown in Example 1, firstly obtain Form A;
[0174] b. Take 100 mg of Form A, add 1 mL of acetonitrile and 2 mL of isopropyl ether to obtain a suspension, stir at room temperature for 4 days, and then centrifuge. Take the precipitate and dry it in vacuum at 30°C overnight to obtain Form C.
[0175] The crystal form C of kuding saponin A was subjected to X-ray powder diffraction measurement. The instrument used and its parameters are shown in Table 4. The data obtained are shown in Table 2, that is, there are characteristic peaks at the 2θ angle shown in Table 2.
[0176] Example 3: Preparation of Ilexanoside A Crystalline Form J and Its X-ray Powder Diffraction Determination
[0177] The specific steps for preparing kudingsaponin A crystal form J are as follows:
[0178] a. The preparation method as shown in Example 1, firstly obtain Form A;
[0179] b. Take 100 mg of Form A, add 3 mL of saturated aqueous solution of ethyl acetate to obtain a suspension, stir at room temperature for 4 days, centrifuge, and dry in vacuo at 30°C overnight to obtain Form J.
[0180] Crystal form J of kudingsaponin A was subjected to X-ray powder diffraction measurement. The instrument used and its parameters are shown in Table 4. The data obtained are shown in Table 3, that is, there are characteristic peaks at the 2θ angle shown in Table 3.
[0181] Example 4: Stability test of kudingsaponin A crystal form A
[0182] The crystal form A prepared in Example 1 was subjected to a stability test under the conditions shown in Table 8. The crystal form A was placed in a low borosilicate glass tube pharmaceutical bottle, and a pharmaceutical composite bag (i.e., an aluminum foil bag plus a small bag of silica gel desiccant) was placed on the outer shell, and the bottle was sealed and stored after vacuuming.
[0183] Table 8: Stability test conditions
[0184]
[0185]
[0186] The neutral properties, moisture, content of kubutan saponin A and related substances of Form A were determined by high performance liquid chromatography. The instrument used was an ultra-high performance liquid chromatograph equipped with a DAD (or PDA) detector. The relevant parameters are as follows:
[0187] Chromatographic column: Agilent C18 (2.1*100mm, 1.8-Micron);
[0188] Mobile phase A: acetonitrile;
[0189] Mobile phase B: ultrapure water;
[0190] Detection wavelength: 225nm;
[0191] Flow rate: 0.6 mL / min;
[0192] Injection volume: 5 μl;
[0193] Column temperature: 38 °C;
[0194] Running time: 28 minutes;
[0195] Isocratic elution: mobile phase A: mobile phase B = 26:74 (V / V);
[0196] Diluent: acetonitrile: water = 30:70 (V / V);
[0197] Blank solution: diluent.
[0198] 1. The specific steps for determining the content of kudingsaponin A are as follows:
[0199] Preparation of impurity A stock solution: Take about 10 mg of impurity A (i.e., kuding saponin B), accurately weigh, place in a 100 mL volumetric flask, dissolve and dilute to the scale with diluent, mix well, and make a solution containing about 100 μg of impurity A per 1 mL, which is the impurity A stock solution.
[0200] Preparation of impurity D stock solution: Same as the above steps for preparing impurity A stock solution, except that impurity A is replaced with impurity D (i.e., kuding saponin C) to prepare a solution containing approximately 100 μg of impurity D per 1 mL.
[0201] Preparation of impurity F stock solution: In the same manner as the above steps for preparing impurity A stock solution, impurity A was replaced with impurity F (i.e., kuding saponin D) to prepare a solution containing approximately 100 μg of impurity F per 1 mL.
[0202] Preparation of resolution solution: weigh about 50 mg of kubutan saponin A accurately, place it in a 100 mL volumetric flask, dissolve and dilute to the mark with diluent, and mix well; then accurately measure 1 mL of the solution and 0.6 mL of each of the impurity A, D, and F stock solutions into a 10 mL volumetric flask, dilute to the mark with diluent, and mix well to prepare a solution containing approximately 50 μg of kubutan saponin A, 6 μg of impurity A, 6 μg of impurity D, and 6 μg of impurity F per 1 mL, as the resolution solution.
[0203] Prepare standard solution 1: weigh about 50 mg of kudingsaponin A reference substance, accurately weigh it, place it in a 100 mL volumetric flask, dissolve it with diluent to the scale, and mix it; accurately measure 1 mL into a 10 mL volumetric flask, dilute it with diluent to the scale, mix it, and make a solution containing about 50 μg of KA per 1 mL as standard solution 1.
[0204] Prepare standard solution 2: Prepare standard solution 2 in parallel with the steps for preparing standard solution 1.
[0205] Prepare the test solution: weigh about 50 mg of the sample, accurately weigh it, place it in a 100 mL volumetric flask, dissolve it and dilute it to the scale with diluent, and mix it well; accurately measure 1 mL of the solution into a 10 mL volumetric flask, dilute it to the scale with diluent, and mix it well (the concentration of the test solution is 50 μg / mL) (prepare two copies in parallel).
[0206] All sample solutions must be filtered through a 0.22 μm PTFE syringe filter before UPLC analysis.
[0207] Injection procedure: Inject blank solution, resolution solution, standard solution 1, standard solution 2, test solution and standard solution 1 back and forth according to the chromatographic conditions, and record the entire chromatographic process.
[0208] Calculation of results: The content of kudingsaponin A was calculated using standard solution 1 by external standard method.
[0209] 2. The specific steps for determining the content of relevant substances are as follows:
[0210] First, prepare impurity A, D, F stock solutions, standard solution 1, and standard solution 2 as described above for determining the content of kudingsaponin A. Second, prepare the following solutions:
[0211] Separation solution: Take 60 mg of kudingsaponin A, accurately weigh it, and place it in a 100 mL volumetric flask. Add 0.9 mL of impurity A, impurity D and impurity F stock solutions respectively, dilute to the scale with diluent, and mix well (the concentrations of kudingsaponin A, impurity A, impurity D and impurity F are 600, 0.9, 0.9 and 0.9 μg / mL respectively).
[0212] Sensitivity solution: Accurately measure 1 mL of standard solution 1 stock solution into a 100 mL volumetric flask, dilute to the scale with diluent, and mix well; accurately measure 3 mL of the solution into a 100 mL volumetric flask, dilute to the scale with diluent, and mix well to make a solution containing approximately KA0.15 μg per 1 mL as the sensitivity solution (equivalent to 0.025% impurity limit solution).
[0213] Test solution: Take 60 mg of kuding saponin A, weigh accurately, place in a 100 mL volumetric flask, dissolve in diluent and dilute to scale, mix well. Prepare two samples in parallel, named TS1 and TS2.
[0214] Control solution: Accurately measure 1 mL of the test solution into a 100 mL volumetric flask and dilute to the mark with diluent. Accurately measure 1 mL of the solution into a 10 mL volumetric flask and dilute to the mark with diluent. Prepare two samples in parallel and name them TSR1 and TSR2.
[0215] All sample solutions must be passed through a 0.22 μm PTFE syringe filter before UPLC analysis.
[0216] Injection procedure: Inject blank solution, resolution solution, sensitivity solution, standard solution 1, standard solution 2, test solution, control solution and standard solution 1 respectively according to the chromatographic conditions, and record the entire chromatographic process.
[0217] Calculation of results: The contents of related substances in the test solution were calculated by the self-control method with correction factors. Among them, the correction factors of impurity A (i.e., kuding saponin B), impurity D (i.e., kuding saponin C), and impurity F (i.e., kuding saponin D) were 1.13, 0.80, and 0.82, respectively.
[0218] Using the above method, the stability data of Form A are shown in Tables 9, 10 and 11.
[0219] Table 9: Long-term test 1
[0220]
[0221] Note: ND means the result is below the detection limit (the detection limits of impurity A, impurity D and impurity F are 0.03%, 0.02%, 0.05% and 0.02% respectively);
[0222] Table 10: Long-term test 2
[0223]
[0224] Note: ND means the result is below the detection limit (the detection limits of impurity A, impurity D and impurity F are 0.03%, 0.02%, 0.05% and 0.02% respectively);
[0225] Table 11: Accelerated test
[0226]
[0227] Note: ND means the result is below the detection limit (the detection limits of impurity A, impurity D and impurity F are 0.03%, 0.02%, 0.05% and 0.02% respectively);
[0228] From the results shown in Tables 9-11, it can be seen that the crystal form A prepared in Example 1 meets the prescribed quality standards regardless of the test conditions, indicating that it has good stability.
[0229] Example 5: Hygroscopicity test of crystalline forms A, C and J of kudingsaponin A
[0230] About 10 mg of each of the crystal forms A, C, and J prepared in Examples 1-3 were taken, and their hygroscopicity was tested by a dynamic moisture sorption instrument (DVS) (test conditions: temperature was 25°C, relative humidity was 0% to 80%), and the hygroscopic characteristics of each crystal form were judged by the standards shown in Table 12 below. The method steps and judgment criteria of this hygroscopic test are detailed in General Rule 9103 of the Pharmacopoeia of the People's Republic of China 2020 Edition (Volume 4) - Guiding Principles for Drug Hygroscopicity Test.
[0231] Table 12: Hygroscopicity criteria
[0232]
[0233]
[0234] In this experiment, the dynamic moisture adsorption (DVS) diagrams of crystal forms A, C, and J are shown in Figure 2. Figure 1d , 2d And the results of its hygroscopicity are shown in Table 13 below:
[0235] Table 13: Hygroscopicity test results of crystal forms A, C, and J
[0236] Crystal form Weight gain (relative humidity: 0% to 80%) Moisture absorption characteristics A 12% Hygroscopic C 1.8% Slightly hygroscopic J 4.7% Hygroscopic
[0237] It can be seen from Table 13 that the hygroscopicity of crystal forms A, C, and J is from large to small: A>J>C. According to the 2020 version of the hygroscopicity standard, crystal form C is slightly hygroscopic; crystal forms A and J are hygroscopic. Crystal form C has obvious advantages in hygroscopic performance.
[0238] Example 6: Stability test of crystalline form J of kudingsaponin A
[0239] Take 25 mg of Form J, spread it in a petri dish, and place it in an open and dark place for 10 days under long-term conditions (temperature: 25°C ± 2°C; relative humidity: 65% ± 10%) and accelerated conditions (temperature: 40°C ± 2°C; relative humidity: 75% ± 10%), and perform X-ray powder diffraction measurement and thermogravimetric analysis on it. The X-ray powder diffractometer used and its parameters are shown in Table 4; the thermogravimetric analyzer used and its parameters are shown in Table 6. The measurement results are shown in the attached Figure 4a and attached Figure 4b shown.
[0240] Depend on Figure 4a It can be seen that: under the conditions of long-term test and accelerated test, the characteristic peaks on the X-ray powder diffraction pattern of Form J did not change, proving that its crystal form has not changed; Figure 4b It can be seen that under the conditions of long-term test and accelerated test, the weight loss of crystal form J did not change. In summary, crystal form J has good stability.
[0241] Example 7: Competition experiment between crystalline form A and crystalline form J of kudingsaponin A
[0242] First, the initial mixed sample was prepared: equal amounts of crystalline form A and crystalline form J samples of kudingsaponin A were taken and mixed evenly, and samples were taken for XRPD detection. The instruments and parameters used are shown in Table 4, and the results are as follows: Figure 5a Comparison chart shown.
[0243] Water was added to the sample to form a suspension, stirred at room temperature, centrifuged after 3 days, and sampled for XRPD detection (wet sample); XRPD was measured after vacuum drying at 30°C (dry sample). The instruments used and their parameters are shown in Table 4. The measurement results are shown in Figure 5b shown.
[0244] By the attached Figure 5b It can be seen that no matter whether the sample is dry or wet, the hydrate obtained by measurement is all crystal form J. Therefore, it can be seen that: under certain conditions, crystal form A tends to be converted into crystal form J.
[0245] Example 8: Preparation of other new crystal forms of kudingsaponin A and X-ray powder diffraction determination thereof
[0246] 1. Preparation of Form B and its X-ray powder diffraction determination
[0247] Preparation method of kuding saponin A crystal form B: as the preparation method shown in Example 1, first prepare crystal form A; take an appropriate amount of crystal form A sample, heat the hot plate to 120° C., and keep warm for 5 minutes to obtain crystal form B.
[0248] The crystal form B obtained above was subjected to X-ray diffraction measurement. The instruments used and their parameters are shown in Table 4. The data obtained are shown in Table 14:
[0249] Table 14: X-ray powder diffraction peak list of Form B
[0250]
[0251]
[0252] Crystalline Form B has characteristic peaks at 2θ angles as described in Table 14 above. In addition, Crystalline Form B can only exist stably under high temperature conditions.
[0253] 2. Preparation of Form D and its X-ray powder diffraction determination
[0254] Take about 100 mg of amorphous kuding saponin A, add 15 mL of isopropanol, ultrasonicate, stir in a 60°C water bath until completely dissolved, then slowly precipitate solid, slowly cool to room temperature, stir for 4 days, centrifuge to obtain Form D.
[0255] The crystal form D obtained above was subjected to X-ray diffraction measurement. The instruments used and their parameters are shown in Table 4. The data obtained are shown in Table 15:
[0256] Table 15: X-ray powder diffraction peak list of Form D
[0257]
[0258]
[0259] Crystalline Form D has characteristic peaks at 2θ angles as described in Table 15 above. In addition, Crystalline Form D can only exist stably in a wet sample that is kept moist.
[0260] 3. Preparation of Form E and its X-ray powder diffraction determination
[0261] Preparation method of crystalline form E of kubutan saponin A: Take about 30 mg of amorphous kubutan saponin A, add 0.8 mL of ethanol and 0.2 mL of water, heat in a 70°C water bath until it is completely dissolved, slowly cool to room temperature, and leave it overnight to precipitate solid to obtain crystalline form E.
[0262] The crystal form E obtained above was subjected to X-ray diffraction measurement. The instruments used and their parameters are shown in Table 4. The data obtained are shown in Table 16:
[0263] Table 16: X-ray powder diffraction peak list of Form E
[0264]
[0265]
[0266] Crystalline Form E has characteristic peaks at 2θ angles as described in Table 16 above. In addition, Crystalline Form E can only exist stably in a wet sample that is kept moist.
[0267] 4. Preparation of Form G and its X-ray powder diffraction determination
[0268] Preparation method of kubutan saponin A crystal form G: Take about 100 mg of amorphous kubutan saponin A, add 3 mL of tetrahydrofuran and 1.2 mL of water, sonicate to completely dissolve it, and leave it open at room temperature to evaporate, to obtain crystal form G.
[0269] The crystal form G obtained above was subjected to X-ray diffraction measurement. The instruments used and their parameters are shown in Table 4. The data obtained are shown in Table 17:
[0270] Table 17: X-ray powder diffraction peak list of Form G
[0271]
[0272]
[0273]
[0274] Crystalline Form G has characteristic peaks at 2θ angles as described in Table 17. In addition, Crystalline Form G can only exist stably in a wet sample that is kept moist.
[0275] 5. Preparation of Form I1 and its X-ray powder diffraction determination
[0276] Preparation method of kubutan saponin A crystal form I1: take about 30 mg of amorphous kubutan saponin A, add 1 mL of trifluoroethanol, sonicate to completely dissolve it, evaporate and dry it in an open air at room temperature to obtain crystal form I1.
[0277] The crystal form I1 obtained above was subjected to X-ray diffraction measurement. The instruments used and their parameters are shown in Table 4. The data obtained are shown in Table 18:
[0278] Table 18: X-ray powder diffraction peak list of Form I1
[0279] 2θ° d interval Relative Strength % 5.108 17.2868 100 6.406 13.7853 94.3 7.684 11.4952 36.6 12.82 6.8993 38.5 13.998 6.3212 34 14.329 6.1761 29.4 14.705 6.0191 33.2 16.091 5.5036 26.4 19.227 4.6123 27.2 20.592 4.3097 18.9 25.806 3.4495 16.6
[0280] Crystalline Form I1 has characteristic peaks at 2θ angles as described in Table 18 above.
[0281] 6. Preparation of Form I2 and its X-ray Powder Diffraction Determination
[0282] Preparation method of bitter saponin A crystal form I2: take about 100 mg of amorphous bitter saponin A, add 3 mL of trifluoroethanol, ultrasonicate until completely dissolved and filter, evaporate to dryness at room temperature, and obtain crystal form I2.
[0283] The crystal form I2 obtained above was subjected to X-ray diffraction measurement. The instruments used and their parameters are shown in Table 4. The data obtained are shown in Table 19:
[0284] Table 19: X-ray powder diffraction peak list of Form I2
[0285]
[0286]
[0287] Form I2 has characteristic peaks at 2θ angles as described in Table 19 above.
[0288] 7. Preparation of Form K and its X-ray Powder Diffraction Determination
[0289] Preparation method of kudingsaponin A crystal form K: take about 100 mg of amorphous kudingsaponin A, add 15 mL of ethanol, ultrasonicate until completely dissolved, filter, concentrate and dry under reduced pressure at 28°C to obtain crystal form K.
[0290] The crystal form K obtained above was subjected to X-ray diffraction measurement. The instruments used and their parameters are shown in Table 4. The data obtained are shown in Table 20:
[0291] Table 20: X-ray powder diffraction peak list of Form K
[0292]
[0293]
[0294] Form K has characteristic peaks at 2θ angles as described in Table 20 above.
[0295] 8. Preparation of Form L and its X-ray Powder Diffraction Determination
[0296] Preparation method of kuding saponin A crystal form L: as the preparation method shown in Example 3, first prepare crystal form J; take an appropriate amount of crystal form J, heat it to 120° C., and keep it warm for 5 minutes to obtain crystal form L.
[0297] The crystal form L obtained above was subjected to X-ray diffraction measurement. The instruments used and their parameters are shown in Table 4. The data obtained are shown in Table 21:
[0298] Table 21: X-ray powder diffraction peak list of Form L
[0299] 2θ° d interval Relative Strength % 3.659 24.1299 13.9 4.76 18.5477 9 6.159 14.3378 1.8 7.902 11.179 11.6 9.541 9.2621 21.9 11.359 7.7833 2 12.284 7.1992 100 12.822 6.8983 3.8 13.604 6.5039 64.6 14.585 6.0682 48 15.424 5.7401 35 16.165 5.4784 41 16.926 5.2341 17.1 17.344 5.1086 17.5 18.165 4.8797 8.9 18.806 4.7147 17.3 19.348 4.5839 6.1 19.969 4.4427 4 20.426 4.3442 12.9 22.266 3.9893 4.6 22.829 3.8921 2.8 23.546 3.7753 6.2 24.767 3.5918 3.9 26.07 3.4152 6.6 26.547 3.3549 2.5 28.629 3.1155 4.7
[0300] Crystalline Form L has a characteristic peak at the 2θ angle as described in Table 21 above. In addition, Crystalline Form L can only exist stably at high temperatures.
[0301] Example 9: Biological activity of kudingsaponin A
[0302] 1. Relaxation effect of kudingsaponin A on bronchial smooth muscle
[0303] First, kubutan saponin A solutions of different concentrations were prepared: 0.3253 g of kubutan saponin A crystal form A obtained in Example 1 was weighed, 1 mL of dimethyl sulfoxide (DMSO) was added to dissolve it, and a kubutan saponin A crystal form A stock solution was prepared, which was then diluted with DMSO to 1 μM, 3.2 μM, 10 μM, and 32 μM kubutan saponin A crystal form A solutions in sequence.
[0304] Secondly, bronchial rings were prepared: 6-week-old C57BL / 6J mice were killed by cervical dislocation, and the left and right bronchi were removed and then bronchial dissection was performed under a stereomicroscope to obtain the left and right bronchi and cut into bronchial rings with a length of about 2 mm.
[0305] Secondly, balance the tension of the bronchial rings: fix the bronchial rings with two metal wires and hang them in a 37°C water bath containing 5 mL of balanced salt solution (Kreb solution), while continuously passing a mixed gas containing 5% carbon dioxide and 95% oxygen; then, balance the bronchial ring tension using a tension transducer and rebalance after pre-stimulation with 60 mM potassium chloride.
[0306] Finally, airway tension measurement and drug administration were performed: the instrument was calibrated and the detection system was zeroed; the tension value A was recorded when the mouse tension was stable; 5 μL of 10 mM melanin concentrating hormone was added to 5 mL of Kreb solution to make the final concentration of 10 μM, and when the bronchial ring contraction tension reached the highest peak, 5 μL of kuding saponin A crystal form A solution of different concentrations (1 μM, 3.2 μM, 10 μM, 32 μM) were added respectively, and the changes in bronchial tension were observed and recorded, and the airway tension relaxation percentage was calculated, as shown in Table 22. Among them, the average tension value 1 minute before the addition of kuding saponin A solution was recorded as B, and the average tension value 20 minutes after the addition of kuding saponin A was recorded as C, and the airway tension relaxation percentage = (B-C) / (B-A).
[0307] Table 22: Bronchial smooth muscle tension relaxation ratio under different concentrations of kuding saponin A
[0308] Ibuproside A concentration Average tension relaxation ratio 1μM -3.57% 3.2μM 21.40% 10μM 42.93% 32μM 50.09%
[0309] It can be seen from Table 22 above that: when the concentration of kuding saponin A is 1 μM, it has no relaxing effect on bronchial smooth muscle; when the concentration of kuding saponin A is 3.2 μM, 10 μM, and 32 μM, bronchial smooth muscle is relaxed to a certain extent, and the higher the concentration of KA, the stronger the relaxing effect on bronchial smooth muscle.
[0310] 2. Anti-inflammatory effects of kudingsaponin A
[0311] First, prepare kuding saponin A solutions of different concentrations. The specific steps are as follows:
[0312] (1) Preparation of 15 mg / mL kubutan saponin A crystal form A stock solution: weigh 0.50990 g of kubutan saponin A crystal form A obtained in Example 1, add 33.993 mL of propylene glycol and ultrasonically dissolve to obtain about 40 mL of 15 mg / mL kubutan saponin A crystal form A stock solution, and store at room temperature away from light;
[0313] (2) Preparation of 1.5 mg / mL Kubutan saponin A solution: Take 2 mL of 15 mg / mL Kubutan saponin A crystal form A stock solution, add 18 mL of 25% propylene glycol to dilute, and obtain 20 mL of 1.5 mg / mL Kubutan saponin A solution, which is prepared and used immediately.
[0314] (3) Preparation of 0.3 mg / mL Kubutan saponin A solution: Measure 4 mL of 1.5 mg / mL Kubutan saponin A solution, add 16 mL of 32.5% propylene glycol to dilute, and obtain 20 mL of 0.3 mg / mL Kubutan saponin A solution, which is prepared and used immediately.
[0315] (4) Preparation of 0.06 mg / mL Kubutan saponin A solution: Measure 3 mL of 0.3 mg / mL Kubutan saponin A working solution, add 12 mL of 32.5% propylene glycol to dilute, and obtain 15 mL of 0.3 mg / mL Kubutan saponin A solution, which is prepared and used immediately.
[0316] Secondly, an asthma mouse model with obvious lung inflammation was constructed: 100 μL 6 mg / mL chicken egg albumin and 4 mg aluminum hydroxide were intraperitoneally injected into Balb / c mice on the first day, 100 μL 3.6 mg / mL chicken egg albumin and 4 mg aluminum hydroxide were injected on the 8th day, and 100 μL 1 mg / mL chicken egg albumin and 4 mg aluminum hydroxide were injected on the 15th day. On the 20th-23rd day, 6 mL 2% chicken egg albumin was used for 30 minutes of aerosol stimulation every day to construct an asthma mouse model with obvious lung inflammation. Among them, 100 μL PBS was used to replace chicken egg albumin in the blank control group mice.
[0317] Finally, nebulization treatment was carried out: starting from the 24th day, nebulization treatment was performed twice a day for 30 minutes each time, with a total of 12 mL of different concentrations (0.06 mg / mL, 0.3 mg / mL, 1.5 mg / mL) of bitter saponin A solution for treatment. One hour after the nebulization treatment, 6 mL of 2% chicken egg white albumin was used for nebulization stimulation for 30 minutes. This was done and stimulated for 15 days; and 24 hours after the last administration and stimulation experiment, that is, sampling began on the 39th day. Before sampling, 12 mL of bitter saponin A solution of the corresponding nebulization treatment concentration was given twice for 30 minutes each time. The above is the experimental group scheme for nebulization treatment of different doses of bitter saponin A. The mice in the negative control group were treated with nebulization instead of bitter saponin A with 30% propylene glycol.
[0318] Flow cytometry was used to detect the proportion of eosinophils (EO) in the leukocytes of the mouse bronchoalveolar lavage fluid samples. Among them, there were 15 mice in the blank group; 12 mice in the negative control group; and 18, 13, and 14 mice in the high, medium, and low concentrations of kuding saponin A experimental groups, respectively. The results are shown in Table 23 below.
[0319] Table 23: Statistical results of eosinophil (EO) percentage
[0320]
[0321] From the results in Table 23, it can be seen that: compared with the blank control group, the proportion of eosinophils in the negative control group was significantly increased, indicating that the asthma mouse model of lung inflammation was successfully constructed; compared with the negative control group, the proportion of eosinophils in the groups treated with various doses of kudingsaponin A decreased, indicating that kudingsaponin A has a certain anti-inflammatory effect.
[0322] Although the present invention has been described with specific examples, it is obvious to those skilled in the art that various changes and modifications may be made to the present invention without departing from the spirit and scope of the present invention. Therefore, the appended claims cover all such changes within the scope of the present invention.
Claims
1. Crystalline form C of kudingsaponin A compound, characterized in that: The X-ray powder diffraction (XRPD) pattern of the crystalline form C has characteristic peaks at the following 2θ angles: 7.8°±0.2°, 12.7°±0.2°, 14.4°±0.2°, 14.9°±0.2°, 16.3°±0.2°, 18.6°±0.2°, and 25.1°±0.2°.
2. The crystal form according to claim 1, characterized in that The X-ray powder diffraction (XRPD) pattern of the Form C also has characteristic peaks at the following 2θ angles: 3.9°±0.2°, 8.3°±0.2°, 13.2°±0.2°, 19.5°±0.2°, and 20.3°±0.2°.
3. The crystal form according to claim 1 or 2, characterized in that The 2θ angle on the X-ray powder diffraction (XRPD) pattern of the Form C is shown below:
4. The crystal form according to claim 1, characterized in that The crystal form C has any one or more of the following characteristics: (1) having an X-ray powder diffraction (XRPD) pattern substantially as shown in FIG. 2a; (2) having a differential scanning calorimetry (DSC) analysis graph substantially as shown in FIG. 2b; (3) having a thermogravimetric analysis (TGA) graph substantially as shown in FIG. 2c ; and (4) having a dynamic moisture sorption (DVS) diagram substantially as shown in FIG. 2d.
5. The method for preparing the crystalline form C of the kubutan saponin A compound according to any one of claims 1 to 4, characterized in that: Form C was prepared by the following method: Dissolve Form A with a solvent to obtain a suspension; stir at room temperature for 3-5 days, and centrifuge; take the obtained solid and vacuum dry it overnight at 25-30°C to obtain Form C; Among them, the X-ray powder diffraction (XRPD) pattern of the crystalline form A has characteristic peaks at the following 2θ angles: 6.7°±0.2°, 7.3°±0.2°, 7.9°±0.2°, 10.5°±0.2°, 10.9°±0.2°, and 14.1°±0.2°.
6. The method according to claim 5, characterized in that The solvent is acetonitrile and isopropyl ether, and the volume ratio of acetonitrile to isopropyl ether is 1:1 to 1:5; the mass volume ratio (g:ml) of Form A to the solvent is 1:20 to 1:
50.
7. The method according to claim 5, characterized in that The X-ray powder diffraction (XRPD) pattern of the crystalline form A also has characteristic peaks at the following 2θ angles: 3.6°±0.2°, 12.8°±0.2°, 13.2°±0.2°, 13.6°±0.2°, 15.2°±0.2°, 16.1°±0.2°, 18.3°±0.2°, and 24.1°±0.2°.
8. The method according to claim 5, characterized in that The 2θ angle on the X-ray powder diffraction (XRPD) pattern of the crystalline form A is as follows:
9. The method according to claim 5, characterized in that The crystal form A has any one or more of the following characteristics: (1) having an X-ray powder diffraction (XRPD) pattern substantially as shown in FIG. 1a; (2) having a differential scanning calorimetry (DSC) analysis graph substantially as shown in FIG. 1b ; (3) having a thermogravimetric analysis (TGA) graph substantially as shown in FIG. 1c ; and (4) having a dynamic moisture sorption (DVS) diagram substantially as shown in FIG. 1d.
10. The method according to claim 5, characterized in that The preparation method of the crystal form A comprises: The extract of Kudingcha is extracted by percolation and concentrated to obtain an extract; the extract is diluted and centrifuged to obtain a crude sample; the crude sample is purified by high pressure chromatography, decolorized, recrystallized, freeze-dried, and finally crushed to obtain crystal form A.
11. The method according to claim 10, characterized in that Pure ethanol or 50-90% (v / v) ethanol-water solution is used for percolation extraction, and the mass ratio of Kudingcha powder to ethanol is 1:2.5-1:1.5; the extract is diluted with water and anhydrous ethanol in succession and centrifuged to obtain a crude sample, the amount of water used is 0.5-1 times the mass of Kudingcha powder, and the amount of anhydrous ethanol used is 0.3-0.8 times the mass of Kudingcha powder.
12. The method according to claim 10, characterized in that The crude sample is dissolved in ethanol or an aqueous solution thereof at 60-90° C., and then placed at a temperature below 10° C. for recrystallization; the obtained crystals are freeze-dried at 0° C., and then dried at 20-28° C., and finally dried at a temperature above 32° C. to obtain Form A, wherein the freeze-drying time is 1-3 hours, the drying time at 20-28° C. is 3-5 hours, and the drying time above 32° C. is 5-8 hours.
13. The method according to claim 5, characterized in that The crystalline form A is prepared by any one of the following methods: Method 1: dissolving amorphous kubutan saponin A in an alcohol solvent to obtain a solution of kubutan saponin A, concentrating the solution until a white precipitate is precipitated and substantially no droplets are generated at the inlet of the evaporation liquid collection container, which is the concentration end point, to obtain a concentrated solution; freeze-drying the concentrated solution to obtain crystalline form A; Method 2: dissolving amorphous kubutan saponin A in an alcohol solvent to obtain a solution of kubutan saponin A, ultrasonically treating the solution, filtering it, and concentrating the filtrate under reduced pressure to obtain a dry solid, which is crystalline form A; Wherein, the alcohol solvent used in methods one and two is ethanol.
14. The method according to claim 13, characterized in that The methods 1 and 2 use ethanol aqueous solution to dissolve amorphous kubutan saponin A.
15. The method according to claim 13, characterized in that In the method 1, after obtaining the dissolved solution of kubutan saponin A, it is first filtered to obtain a clear solution, and then the clear solution is concentrated, and filtered using a filter membrane with a pore size of less than 5 microns. The dissolved solution or the clear solution is concentrated using a rotary evaporator, and the concentration is carried out in a water bath at 50-60° C., the rotation speed is controlled to 30-80 rpm, and the vacuum degree is controlled to be not less than 0.08 Mpa.
16. Use of the crystalline form C of the kubutan saponin A compound according to any one of claims 1 to 4 in the preparation of a medicament for treating lung diseases.
17. The use according to claim 16, characterized in that The lung disease is chronic obstructive pulmonary disease or asthma.
18. A pharmaceutical composition for treating lung diseases, characterized in that: The pharmaceutical composition comprises a therapeutically effective amount of the crystalline form C of the kubutasaponin A compound according to any one of claims 1 to 4 and a pharmaceutically acceptable carrier.
19. The pharmaceutical composition according to claim 18, characterized in that The dosage form of the pharmaceutical composition is an inhalation preparation.
20. The pharmaceutical composition according to claim 19, characterized in that The inhalation preparation is an inhalation powder, an inhalation aerosol, an inhalation spray, an inhalation suspension or an inhalation solution.
21. The pharmaceutical composition according to claim 18, characterized in that The pharmaceutically acceptable carrier includes one or more of a lubricant, a glidant, a propellant, a cosolvent, a cosolvent, a diluent, a stabilizer and an antibacterial agent.
22. The pharmaceutical composition according to claim 18, characterized in that The pharmaceutical carrier is lactose.
23. The pharmaceutical composition according to claim 18, characterized in that The pharmaceutical carrier is polyethylene glycol 200, ethanol and 1,1,1,2-tetrafluoroethane.
